Statera Biopharma Company Top Management

Statera Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2385) % which means that it has lost $0.2385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8694) %, meaning that it created substantial loss on money invested by shareholders. Statera Biopharma's management efficiency ratios could be used to measure how well Statera Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Statera Biopharma shows a total of 54.66 Million outstanding shares. Statera Biopharma has 15.93 % of its outstanding shares held by insiders and 5.41 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in pink sheets such as Statera Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Statera Biopharma, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Statera Biopharma Workforce Comparison

Statera Biopharma Benchmark Summation

Statera Biopharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Statera Biopharma often depends on how effective the management is. Statera Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Statera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Statera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Statera Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Statera Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Statera Biopharma's management manipulating its earnings.

When running Statera Biopharma's price analysis, check to measure Statera Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Statera Biopharma is operating at the current time. Most of Statera Biopharma's value examination focuses on studying past and present price action to predict the probability of Statera Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Statera Biopharma's price. Additionally, you may evaluate how the addition of Statera Biopharma to your portfolios can decrease your overall portfolio volatility.